Pyroglutamate API Manufacturers & Suppliers

Looking for Pyroglutamate API 149-87-1?

Description:

Here you will find a list of producers, manufacturers and distributors of Pyroglutamate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Pyroglutamate 

Synonyms:

PCA , Pyroglutamic acid  

Cas Number:

149-87-1 

DrugBank number:

DB11245 

Unique Ingredient Identifier:

6VT1YZM21H

Pyroglutamate is a type of Nervous System Agents

Nervous System Agents are a crucial subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that target the intricate workings of the nervous system. These agents play a pivotal role in managing various neurological conditions and disorders by modulating the neurotransmitters and receptors involved in nerve signaling.

Nervous System Agents encompass a wide range of pharmaceutical APIs, including but not limited to antiepileptic drugs, antidepressants, antipsychotics, anxiolytics, and analgesics. These APIs work by interacting with specific molecular targets in the nervous system, such as neurotransmitter receptors or enzymes involved in neurotransmitter synthesis or degradation.

One notable class of Nervous System Agents is CGRP (Calcitonin Gene-Related Peptide) antagonists. CGRP is a neuropeptide involved in the transmission of pain signals in the central and peripheral nervous systems. CGRP antagonists act by blocking the CGRP receptors, thereby inhibiting the CGRP-mediated pain pathway.

CGRP antagonists have shown promising therapeutic potential in the management of migraine headaches. By selectively targeting CGRP receptors, these pharmaceutical APIs can effectively prevent or reduce the frequency and severity of migraines. They offer an alternative treatment option for patients who do not respond well to conventional migraine medications.

The development and utilization of Nervous System Agents, including CGRP antagonists, represent a significant advancement in the field of neuropharmacology. These APIs provide healthcare professionals with valuable tools to address various neurological disorders, ultimately improving patients' quality of life. Continued research and innovation in this subcategory are expected to lead to further breakthroughs in the treatment of nervous system-related conditions.

Pyroglutamate (Nervous System Agents), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.